Dr. Gareth Morgan joins our dynamic team of researchers as a Research Assistant Professor
We are ecstatic to introduce Dr. Gareth Morgan as he becomes a member of the BU Amyloidosis Center. Dr. Morgan joins our dynamic team of researchers as a Research Assistant Professor from today. We extend our warm welcome to Dr. Morgan and wish him the best in continuing basic and translational research in AL amyloidosis. […]
Hematologist on our multidisciplinary clinical team, Dr. Mark Sloan, @jmarksloan, was named as an Evans Outstanding Clinician
We are proud to announce that the hematologist on our multidisciplinary clinical team, Dr. Mark Sloan, @jmarksloan, was named as an Evans Outstanding Clinician. He is being recognized as for clinical skills, attributes and professionalism that define excellence. This award is intended to acknowledge the value of clinical medicine and honor clinical role models among the […]
2019 House and Senate language on Amyloidosis
August 24, 2018 Last night the Senate passed the fiscal year 2019 Labor HHS bill. This is the first time the bill has passed the Senate floor in a decade. This gives more emphasis to language included in the Senate and House reports on Amyloidosis and the hope for completing a House Senate conference and […]
FDA COULD MAKE A HISTORIC DECISION FOR AMYLOIDOSIS PATIENTS
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
Repurposing a cardiac test to help diagnose cardiac transthyretin amyloidosis
Featuring Dr. Frederick L. Ruberg, our senior cardiologist | Read more below https://www.cardiovascularbusiness.com/topics/imaging/resurrecting-tc-99m-pyp-cardiac-amyloidosis-therapies-emerge-old-test-gains-new
Proud to Present Dr. John Berk’s Research in hereditary ATTR Amyloidosis in New England Journal of Medicine
We are proud to announce 2 publications in the New England Journal of Medicine highlighting Dr. John Berk’s research in hereditary ATTR amyloidosis. You can find both articles linked below. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis NEJM | PubMed Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis NEJM | PubMed Congratulations to Dr. […]
3rd Annual Fit To Be Tied Race Wrap-Up
We would like to give a big shout-out to everyone that came out to the 3rd Annual Fit to Be Tied in support for Amyloidosis, which took place on May 20th, 2018 in Onondaga Lake Park in Liverpool, NY. We would also like to sincerely thank Ms. Floris Palmer and everyone who makes Fit to […]
Ann Peel Urges the US Congress to Support Amyloidosis Research for 2019
Ann Peel gave her testimony on amyloidosis to the House and Senate Appropriations Committees on April 26th, 2018. The testimony seeks support for Amyloidosis programs from Congress in the fiscal year 2019 Labor, Health Services and Education Appropriations bill. Please see her complete statement below. We are very grateful to Ann and Terry Peel for their dedication to […]
Dr. John Berk Speaks at 2018 AAN Meeting on Phase 3 Inotersen Results in hATTR
This past weekend, Dr. John Berk had the privilege of speaking at the 2018 American Academy of Neurology Annual Meeting in Los Angeles, California. Dr. Berk gave an impressive talk on the phase 3 inotersen results in hATTR to a packed house of neurologists. You can read more about the meeting here: https://www.aan.com/conferences-community/annual-meeting/
NEWS: Prothena Discontinues Development of NEOD001 for AL Amyloidosis
On April 23rd, 2018, Prothena Corporation plc announced the discontinuation of the development of NEOD001, an investigational monoclonal antibody targeting circulating soluble and deposited amyloid found in patients with AL Amyloidosis. The decision was made based on results from the Phase 2b PRONTO study and a fuity analysis of the Phase 3 VITAL study, according […]